Literature DB >> 19466425

Anti-inflammatory mechanism of tocilizumab, a humanized anti-IL-6R antibody: effect on the expression of chemokine and adhesion molecule.

Miho Suzuki1, Misato Hashizume, Hiroto Yoshida, Masahiko Mihara.   

Abstract

We studied the influence of IL-6 on chemokine production from peripheral blood mononuclear cells (PBMC), fibroblastic synovial cells and human umbilical vessel endothelial cells (HUVEC). Moreover, we examined the effect of IL-6 on the adhesion of U937 cells to HUVEC. For chemokine production, PBMC, fibroblastic synovial cells and HUVEC were cultured with IL-6 or IL-6 + soluble IL-6R (sIL-6R) for 24 h and then the production of MCP-1 and IL-8 were measured in supernatants. IL-6 and IL-6 + sIL-6R induced production of both MCP-1 and IL-8 in PBMC and synovial cells, respectively. In HUVEC, IL-6 + sIL-6R induced MCP-1 production, but inhibited IL-8 production. For adhesion molecule expression, the production of soluble form of adhesion molecules in HUVEC culture supernatant were measured by ELISA and the expression of adhesion molecules on cell surface were examined by flow cytometry analysis. Soluble ICAM-1 was detectable in IL-6 + sIL-6R-treated HUVEC and IL-6 + sIL-6R-induced ICAM-1 expression on cell membrane of HUVEC. In addition, U937 cells were added to HUVEC, which were pre-treated with IL-6 + sIL-6R for 24 h, and 3 h later attached U937 cells were counted. The adhesion of U937 cells to HUVEC was augmented when HUVEC was pretreated by IL-6 + sIL-6R. This adhesion was suppressed by anti-ICAM-1 antibody and anti-IL-6R antibody, but not by antibodies against VCAM-1 or E-selectin. In conclusion, IL-6 signaling plays an important role in inflammatory cell migration by increasing the rate of cell adhesion and by inducing chemokine production in inflamed joints.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19466425     DOI: 10.1007/s00296-009-0953-0

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  19 in total

1.  Soluble forms of E-selectin, ICAM-1 and VCAM-1 are present in the supernatants of cytokine activated cultured endothelial cells.

Authors:  R Pigott; L P Dillon; I H Hemingway; A J Gearing
Journal:  Biochem Biophys Res Commun       Date:  1992-09-16       Impact factor: 3.575

2.  Migration of neutrophils across endothelial monolayers is stimulated by treatment of the monolayers with interleukin-1 or tumor necrosis factor-alpha.

Authors:  M B Furie; D D McHugh
Journal:  J Immunol       Date:  1989-11-15       Impact factor: 5.422

Review 3.  Mechanisms of human lymphocyte migration and their role in the pathogenesis of disease.

Authors:  S T Pals; E Horst; R J Scheper; C J Meijer
Journal:  Immunol Rev       Date:  1989-04       Impact factor: 12.988

4.  Production of soluble ICAM-1 from human endothelial cells induced by IL-1 beta and TNF-alpha.

Authors:  M Hashimoto; M Shingu; I Ezaki; M Nobunaga; M Minamihara; K Kato; H Sumioki
Journal:  Inflammation       Date:  1994-04       Impact factor: 4.092

5.  Concentrations and origins of soluble interleukin 6 receptor-alpha in serum and synovial fluid.

Authors:  A Desgeorges; C Gabay; P Silacci; D Novick; P Roux-Lombard; G Grau; J M Dayer; T Vischer; P A Guerne
Journal:  J Rheumatol       Date:  1997-08       Impact factor: 4.666

6.  Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial.

Authors:  Josef S Smolen; Andre Beaulieu; Andrea Rubbert-Roth; Cesar Ramos-Remus; Josef Rovensky; Emma Alecock; Thasia Woodworth; Rieke Alten
Journal:  Lancet       Date:  2008-03-22       Impact factor: 79.321

7.  Evidence for the involvement of carbohydrate moieties in the adhesion of U937 cells to tumor necrosis factor-alpha (TNFalpha)-stimulated vascular endothelium in vitro.

Authors:  C P Sung; B Strorer; A Arleth; J Stadel; G Feuerstein
Journal:  Agents Actions       Date:  1991-09

8.  Enhanced production of neutrophil-activating peptide-1/interleukin-8 in rheumatoid arthritis.

Authors:  M Seitz; B Dewald; N Gerber; M Baggiolini
Journal:  J Clin Invest       Date:  1991-02       Impact factor: 14.808

9.  Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial.

Authors:  Norihiro Nishimoto; Kazuyuki Yoshizaki; Nobuyuki Miyasaka; Kazuhiko Yamamoto; Shinichi Kawai; Tsutomu Takeuchi; Jun Hashimoto; Junichi Azuma; Tadamitsu Kishimoto
Journal:  Arthritis Rheum       Date:  2004-06

10.  Soluble intercellular adhesion molecule-1 (ICAM-1) antigen in patients with rheumatoid arthritis.

Authors:  S Aoki; K Imai; A Yachi
Journal:  Scand J Immunol       Date:  1993-11       Impact factor: 3.487

View more
  26 in total

Review 1.  Selected cytokine pathways in rheumatoid arthritis.

Authors:  Mélissa Noack; Pierre Miossec
Journal:  Semin Immunopathol       Date:  2017-02-17       Impact factor: 9.623

2.  Radiation damage and radioprotectants: new concepts in the era of molecular medicine.

Authors:  M I Koukourakis
Journal:  Br J Radiol       Date:  2012-01-31       Impact factor: 3.039

3.  Correlation Between the Expression of MicroRNA-301a-3p and the Proportion of Th17 Cells in Patients with Rheumatoid Arthritis.

Authors:  Xinyi Tang; Kai Yin; Hongsheng Zhu; Jie Tian; Dong Shen; Lixian Yi; Ke Rui; Jie Ma; Huaxi Xu; Shengjun Wang
Journal:  Inflammation       Date:  2016-04       Impact factor: 4.092

4.  Serum levels of selected chemokines in systemic lupus erythematosus patients.

Authors:  Eugeniusz Hrycek; Andrzej Franek; Edward Błaszczak; Justyna Dworak; Antoni Hrycek
Journal:  Rheumatol Int       Date:  2012-03-30       Impact factor: 2.631

5.  Blockade of interleukin-6 receptor enhances the anti-arthritic effect of glucocorticoids without decreasing bone mineral density in mice with collagen-induced arthritis.

Authors:  M Suzuki; H Yoshida; M Hashizume; K Tanaka; Y Matsumoto
Journal:  Clin Exp Immunol       Date:  2015-08-31       Impact factor: 4.330

Review 6.  Rheumatoid arthritis: advances in treatment strategies.

Authors:  Peeyush Prasad; Sneha Verma; Nirmal Kumar Ganguly; Ved Chaturvedi; Shivani Arora Mittal
Journal:  Mol Cell Biochem       Date:  2022-06-21       Impact factor: 3.396

Review 7.  [Methotrexate as combination partner of TNF inhibitors and tocilizumab: what is reasonable from an immunological viewpoint?].

Authors:  T Witte
Journal:  Z Rheumatol       Date:  2013-04       Impact factor: 1.372

Review 8.  Inflammation induced loss of skeletal muscle.

Authors:  Priya Londhe; Denis C Guttridge
Journal:  Bone       Date:  2015-11       Impact factor: 4.398

9.  The roles of interleukin-6 in the pathogenesis of rheumatoid arthritis.

Authors:  Misato Hashizume; Masahiko Mihara
Journal:  Arthritis       Date:  2011-05-26

Review 10.  Interleukin 6 and rheumatoid arthritis.

Authors:  Yuji Yoshida; Toshio Tanaka
Journal:  Biomed Res Int       Date:  2014-01-12       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.